Skip to main content

Moderna, Inc. COVID revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

COVID revenue at Moderna, Inc. came to $1.2B for the quarter to 30 Sep 2026, up 28.1% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Nov 2026.

By quarter

$1.8BSep 2023$167.0MMar 2024$184.0MJun 2024$1.8BSep 2024$923.0MDec 2024$84.0MMar 2025$114.0MJun 2025$971.0MSep 2025$642.0MDec 2025$345.0MMar 2026$91.0MJun 2026$1.2BSep 2026
Moderna, Inc. COVID revenue, every reported period
Period endingCOVID revenueChange on a yearFiled
30 Sep 2026$1.2Bup 28.1%6 Nov 2026
30 Jun 2026$91.0Mdown 20.2%31 Jul 2026
31 Mar 2026$345.0Mup 310.7%1 May 2026
31 Dec 2025$642.0Mdown 30.4%20 Feb 2026
30 Sep 2025$971.0Mdown 46.4%6 Nov 2025
30 Jun 2025$114.0Mdown 38.0%1 Aug 2025
31 Mar 2025$84.0Mdown 49.7%1 May 2025
31 Dec 2024$923.0M—21 Feb 2025
30 Sep 2024$1.8Bup 3.0%7 Nov 2024
30 Jun 2024$184.0M—1 Aug 2024
31 Mar 2024$167.0M—2 May 2024
30 Sep 2023$1.8B—3 Nov 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: Stand-ready manufacturing revenue · RSV revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · United States revenue · Rest of world revenue · Europe revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.